# Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

> **NCT06050317** · PHASE2 · RECRUITING · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 25 (estimated)

## Conditions studied

- Pancreas Cancer

## Interventions

- **DRUG:** Sintilimab Plus mFFN or NALIRIFOX and Radiation

## Key facts

- **NCT ID:** NCT06050317
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-18
- **Primary completion:** 2025-08-18
- **Final completion:** 2026-08-18
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06050317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06050317, "Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06050317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*